Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Estee Lauder Companies Inc (EL) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Estee Lauder Companies IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Estee Lauder Companies Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.7 (market cap $29.60B), while Estee Lauder Companies Inc trades at $88.63 (market cap $31.76B). The key difference: Alnylam Pharmaceuticals, Inc. and Estee Lauder Companies Inc are close in size by market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYEL
Market Cap
$29.60B$31.76B
Sector
HealthConsumer Staples
52-Week High
$491.22$119.61
52-Week Low
$205.48$67.23
Enterprise Value
$27.56B$37.93B
Dividend Yield
1.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.

The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.

Estee Lauder Companies Inc

Estée Lauder (EL) trades at $87.19, down 1.31% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with a net loss of $1.13B in 2025 and negative profit margins, though recent quarters have consistently beaten EPS expectations. Analyst sentiment is divided with a Hold consensus and $91.67 price target, while institutional activity shows significant position changes including Bank of America's 950.9% stake increase in Q1 2026.

The stock presents a recovery opportunity with strong brand positioning and recent product launches like the Glimmer fragrance, but faces headwinds from declining revenues and profitability. Near-term catalysts include the upcoming Q2 2026 earnings report where EL is expected to post $0.3193 EPS. The key risk remains execution on margin improvement amid competitive pressures in the beauty sector.

Returns comparison

Trailing returns across standard periods

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Estee Lauder Companies Inc

Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.

Read more on EL